CHICAGO HIGHLIGHTS 2024 – BREAST ROUNDTABLE DISCUSSION: postMONARCH

Icon Chair Speaker

Chair

Dr. Christine Simmons

Icon Chair Speaker

Panelists

Dr. Christine Brezden-Masley
Dr. Heather McArthur

This program has been made possible through unrestricted support from Eli Lilly

 

Studies/trials discussed:

  • postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy.